Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

The pharmacological treatment of depression consists of stages of trial and error, with less than 40% of patients achieving remission during first medication trial. However, in a large, randomized-controlled trial (RCT) in the U.S. (“GUIDED”), significant improvements in response and remission rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiwari, Arun K., Zai, Clement C., Altar, C. Anthony, Tanner, Julie-Anne, Davies, Paige E., Traxler, Paul, Li, James, Cogan, Elizabeth S., Kucera, Matthew T., Gugila, Ana, Braganza, Nicole, Emmerson, Heather, Zai, Gwyneth, Müller, Daniel J., Levitan, Robert, Kloiber, Stefan, Daskalakis, Zafiris J., Frey, Benicio N., Bowen, James M., Tarride, Jean-Eric, Tytus, Richard, Chandrasena, Ranjith, Voudouris, Nicholas, Taylor, Valerie H., Tempier, Raymond, Sharma, Verinder, Vasudev, Akshya, Dzongowski, Peter, Pliamm, Lew, Greenspoon, Todd, Dechairo, Bryan M., Kennedy, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921325/
https://www.ncbi.nlm.nih.gov/pubmed/35288545
http://dx.doi.org/10.1038/s41398-022-01847-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921325/
https://www.ncbi.nlm.nih.gov/pubmed/35288545
http://dx.doi.org/10.1038/s41398-022-01847-8

Ejemplares similares